LTS Corp Revenue and Competitors

LTS is the global leader in the development and manufacture of transdermal systems and oral thin films. The products developed by LTS comprise a multitude of innovations, including the world-wide first nicotine patch as well as the only patch against Parkinson's and Restless-Legs-Syndrome. This is also the first medication in the world which was developed as a patch formulation right from the very beginning. The innovation capability of LTS led the way for oral thin film products on the market with the introduction of Listeriner Pocketpaksr, which dominate the North American market. LTS Corp has already produced more than a billion strips in the first three years after market launching. More than 5,000 patents reinforce our top position in development of this technologies. Since the end of the 1990s, LTS is also the principal shareholder of "CRS Clinical Research Services", which conducts phases I to IV clinical trials. LTS offers the entire service spectrum, starting with development and continuing to clinical trials and production up to final packaging. It began with the vision of the transdermal therapeutic system and developed into a success story sustained to this day. In 1984 the LTS LOHMANN Therapie-System GmbH & Co. KG was founded in Neuwied; soon afterwards the first successful products were already being marketed, including a nitroglycerine patch for the preventive treatment of angina pectoris and the world-wide first nicotine patch. LTS was founded as a subsidiary of the Lohmann Group. The former parent company Lohmann was founded in 1851 and is active in different business sectors - medical products, adhesive tape systems, and spunbonded fabrics. In 1999 the company was converted into a stock company. In the more than 26 years of the company's existence, LTS has expanded into one of the world-wide principal suppliers of transdermal and oral systems for the international pharmaceutical industry.